Condition
Malignant Neoplasms clinical trials and research
As of November 12, 2026, Find a Trial lists 6 Malignant Neoplasms clinical trials that are recruiting, at sites in 23 countries (most in United States (3), South Korea (2), China (2)). By phase: Phase 1 (2), Phase 2 (1), Phase 3 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 6Clinical trials
- 23Countries
Newest Malignant Neoplasms clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| YKYY031 injection in advanced solid tumors in adults | Phase 1 | Beijing, Beijing Municipality and 1 other locations | Recruiting | Jun 8, 2026 |
| SLC-3010 plus axitinib versus axitinib alone for second-line treatment of advanced clear cell kidney cancer | Phase 2 | Seoul | Recruiting | Mar 13, 2026 |
| Extension program for people previously treated with belzutifan (MK-6482) | Phase 3 | Boston, Massachusetts and 56 other locations | Recruiting | Feb 12, 2026 |
| DEG6498 for people with advanced solid tumors | Phase 1 | Beijing, Beijing Municipality and 2 other locations | Recruiting | Nov 24, 2025 |
| Understanding sexual side effects after radiotherapy in female cancer patients | — | Atlanta, Georgia and 2 other locations | Recruiting | May 27, 2022 |
| Collection of blood and tissue samples from patients with suspected or confirmed cancer | — | Bethesda, Maryland | Recruiting | Nov 15, 2001 |
All recruiting trials (6)
-
YKYY031 injection in advanced solid tumors in adults
A phase 1 trial tests YKYY031 given by injection in adults with advanced solid tumors who have few other treatment options to see if it is safe and how it behaves in the body.
-
SLC-3010 plus axitinib versus axitinib alone for second-line treatment of advanced clear cell kidney cancer
This trial tests whether adding SLC-3010 to axitinib works better than axitinib alone for adults with locally advanced or metastatic clear cell kidney cancer who need second-line treatment.
-
Extension program for people previously treated with belzutifan (MK-6482)
This extension lets people with advanced solid tumors or VHL-related tumors who were already taking belzutifan in another study continue the drug so researchers can see how long they live and watch for long-term effects.
-
DEG6498 for people with advanced solid tumors
This Phase 1 study will try once-daily oral DEG6498 in adults with advanced solid tumors, including BRAF-mutant cancers and liver cancer, who have no standard treatment to see if it is safe and shows signs of anti-tumor activity.
-
Understanding sexual side effects after radiotherapy in female cancer patients
This study is trying to understand how radiotherapy and other cancer treatments affect sexual health in women with cancer to help improve their quality of life.
-
Collection of blood and tissue samples from patients with suspected or confirmed cancer
This study is collecting blood and tissue samples from patients with suspected or confirmed cancer to help researchers learn more about how these cancers develop and find new treatment options.
Related topics
Quick answers
How many Malignant Neoplasms clinical trials are recruiting right now?
6, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 23 countries. The most sites are in United States (3 trials), South Korea (2 trials), China (2 trials), Australia (1 trial), Belgium (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 2, Phase 2: 1, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.